It was developed by Australian researchers, the new flexible vaccine can be an important step forward in TB Control (TB).
There is currently one vaccine approved against the disease, BCG (Bacillus Calmette-Gérin), which, despite its effectiveness, can be variable.
After the success of Covid-19 vaccines, the researchers have investigated that a flexible technique of tuberculosis can be used. The challenge was that although Covid-19 was caused by a virus, tuberculosis is bacteria, so it was not clear whether the protection based on us could be durable.
The new vaccine named MRNACV2 Cracks Cysvac2 protein from breaking the fast tuberculosis. During experiments on mice, vaccination caused a strong immune responseHigh Ti -cells and antibodies. The number of bacteria in the lungs of mice that were vaccinated after the infection.
It is especially important that the new vaccine also works well as a reminder of the mice that previously received BCG vaccination, which greatly improves long -term protection.
Professor Jimmy Trekas, the first researcher at the Sydney Institute of Infectious Diseases, says this is a great progress in developing the TB vaccine. The next step is to improve the vaccine in animal experiments, followed by human clinical trials.
Dr. Claudio Cobas, a researcher at the Centennial Institute, confirmed that flexible vaccines are not only effective against Covid-19, as confirmed by Dr. Claudio Cobas, a researcher at the Centennial Institute. This technology provides a cost -effective, cost -effective platform that can be rapidly spread against various diseases and a revolution can occur in many diseases, including tuberculosis.
The cover image is an illustration. Cover photo source: Getty Images
